<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04871347</url>
  </required_header>
  <id_info>
    <org_study_id>TWP-101-12</org_study_id>
    <nct_id>NCT04871347</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor</brief_title>
  <official_title>A Multi-center, Phase Ia/Ib, Open Clinical Study to Evaluate the Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong TheraWisdom Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong TheraWisdom Biopharma Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, phase Ia/Ib, open clinical study to evaluate the safety and efficacy&#xD;
      of TWP-101 in patients with advanced solid tumor. This study consists of two parts (Part A&#xD;
      and Part B). Part A was a dose escalation study, and Part B was a dose expansion study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity (DLT)</measure>
    <time_frame>From the first dose of study drug up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events and serious adverse event (defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE V5.0)) and irAE.</measure>
    <time_frame>From enrollment until 90 days after the last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) by RECIST Version 1.1</measure>
    <time_frame>From first dose to disease progression or end of study, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From first dose to disease progression, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR).</measure>
    <time_frame>From first dose to disease progression or end of study, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS).</measure>
    <time_frame>From first dose to disease progression or end of study, an average of 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured plasma concentration (Cmax) of TWP-101.</measure>
    <time_frame>From first dose until 90 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) of TWP-101.</measure>
    <time_frame>From first dose until 90 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2) of TWP-101.</measure>
    <time_frame>From first dose until 90 days after the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity profile of TWP-101.</measure>
    <time_frame>From first dose until 90 days after the last dose</time_frame>
    <description>Blood samples will be collected from subjects post treatment for assessment to detect the presence of anti-drug antibodies and neutralizing antibodies by meso scale discovery(MSD).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three dose levels of TWP-101 will be tested by a conventional 3 + 3 study design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TWP-101</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Dose Escalation Cohort</arm_group_label>
    <arm_group_label>Dose Expansion Cohort</arm_group_label>
    <other_name>Sytalizumab Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically or cytologically confirmed advanced solid tumor that failed, couldn't&#xD;
             tolerate or refused standard treatments;&#xD;
&#xD;
          -  ECOG score 0 or 1;&#xD;
&#xD;
          -  At least 1 measurable lesion according to RECIST 1.1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to any ingredient of TWP-101;&#xD;
&#xD;
          -  Receiving any anti-cancer drugs within 4 weeks;&#xD;
&#xD;
          -  History of serious systemic diseases;&#xD;
&#xD;
          -  History of serious autoimmune diseases;&#xD;
&#xD;
          -  Pregnancy or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shengbin Ren</last_name>
    <phone>8021-60167707</phone>
    <email>shengbin.ren@therawisdom.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qingyuan Zhang</last_name>
      <phone>0451-86298070</phone>
      <email>sy86298276@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

